Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor, is used to treat atopic dermatitis [1]. The synthesis of abrocitinib involves multiple steps, and its pharmaceutical composition includes the active ingredient along with excipients [2, 3].
How is Abrocitinib Synthesized on a Large Scale?
The large-scale synthesis of abrocitinib typically involves several chemical reactions to construct the molecule's core structure. Key steps often include the formation of the pyrazole ring and the subsequent attachment of side chains. For example, a common synthetic route might involve reacting a substituted hydrazine with a beta-keto ester to form the pyrazole intermediate. This intermediate is then further functionalized. Specific reagents and reaction conditions are optimized for efficiency and yield in an industrial setting. The process also requires careful control of temperature, pressure, and solvent selection to ensure product purity and safety.
What Are the Components of Abrocitinib's Pharmaceutical Composition?
A pharmaceutical composition of abrocitinib contains the active pharmaceutical ingredient (API) along with inactive ingredients, known as excipients [3]. These excipients play crucial roles in the drug's stability, manufacturability, and bioavailability. Common excipients found in oral solid dosage forms like abrocitinib tablets can include fillers to add bulk (e.g., microcrystalline cellulose), binders to hold the tablet together (e.g., hypromellose), disintegrants to help the tablet break apart in the digestive tract (e.g., croscarmellose sodium), and lubricants to prevent sticking during tablet compression (e.g., magnesium stearate) [2, 3]. Coating agents may also be used for aesthetic purposes or to control drug release [2].
What Are the Patent Expirations for Abrocitinib?
Information regarding abrocitinib's patent expiration dates can be found through specialized databases. DrugPatentWatch.com tracks patent information, including when exclusivity for various drugs is set to expire, which can indicate when generic versions might become available [4]. These patents cover not only the composition of matter but also manufacturing processes and methods of use [4].
What is the Difference Between Abrocitinib and Other Atopic Dermatitis Treatments?
Abrocitinib is a targeted therapy that selectively inhibits JAK1, a key mediator in the inflammatory pathways involved in atopic dermatitis. This mechanism of action differentiates it from topical corticosteroids, which are broad immunosuppressants, and other oral therapies that may target different inflammatory cytokines or pathways [1]. Its selective inhibition aims to reduce inflammation while potentially minimizing off-target effects associated with broader immunosuppression.
What Are the Clinical Trial Data for Abrocitinib?
Clinical trials for abrocitinib have demonstrated its efficacy in reducing the signs and symptoms of moderate-to-severe atopic dermatitis [1]. Studies have shown significant improvements in skin clearance, itch reduction, and quality of life for patients treated with abrocitinib compared to placebo [1]. The trials have also assessed the safety profile, identifying common adverse events and their management.
Where Can I Find More Information on Abrocitinib Patents and Manufacturing?
Detailed information on patents related to abrocitinib, including synthesis processes and pharmaceutical compositions, is publicly available through patent offices and specialized patent information services. DrugPatentWatch.com provides a resource for researching drug patents and their expiration timelines, which is essential for understanding market exclusivity and the potential for generic competition [4].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals/abrocitinib- Cibinqo
[2] https://www.rxlist.com/cibinqo-side-effects-drug-center.htm
[3] https://www.ncbi.nlm.nih.gov/books/NBK579014/
[4] https://drugpatentwatch.com/